In Q3'25, Eli Lilly's (LLY) Cardiometabolic Health segment generated $13.18B in revenue, marking the highest contribution among all segments and driving the overall quarterly total. Oncology followed with $2.41B, Immunology at $1.36B, Neuroscience at $0.32B, and Other at $0.34B, reflecting a robust performance in the latest period ending September 2025. From Q4'22 to Q3'25, the Cardiometabolic Health segment exhibited strong growth, surging from $3.98B to $13.18B with consistent upward momentum, particularly accelerating post-Q2'24 to become the dominant revenue driver at over 70% of the total in recent quarters. Oncology showed steady expansion from $1.65B to $2.41B, while Immunology grew moderately from $0.93B to $1.36B; Neuroscience remained volatile and relatively flat around $0.3B-$0.4B except for an anomaly in Q3'23 ($1.77B), and Other hovered below $0.4B with minor fluctuations. Overall, the stacked bar chart highlights a bullish trend in core therapeutic areas, underscoring LLY's increasing reliance on cardiometabolic and oncology for revenue expansion across the 12-quarter period. ## Explanation of Reasoning - **Latest Data Point Focus**: The first paragraph centers on Q3'25 values, using compressed formats (e.g., $13.18B) per the large-number rules and fiscal labels from the data, while noting segment distribution as required for revenue breakdown charts. - **Trend Analysis**: The second paragraph identifies overall growth (bullish trend), key patterns (e.g., acceleration in Cardiometabolic), significant changes (e.g., Neuroscience anomaly), and dominant segments, drawing from the time-series data spanning Q4'22 to Q3'25 without referencing calendar dates. - **Compliance with Rules**: Output is limited to two paragraphs (3 sentences total), professional tone, specific numbers in USD with valueFormatType applied, and no technical terms for missing data (none present). Trends are derived directly from the provided values, emphasizing growth/decline patterns for financial analysts.